Illumina

Illumina, a leading San Diego-based biotech company specializing in DNA-sequencing technology, is laying off 111 employees at its headquarters, effective March 12, 2024. This latest workforce reduction, announced in January, follows a challenging period marked by regulatory battles and shareholder activism. The company, which had approximately 10,200 global employees as of early 2023, is restructuring after losing a federal antitrust case, forcing it to divest Grail, a $7 billion cancer-testing startup it acquired in 2021. These layoffs, which include vice presidents, scientists, and engineers, are part of broader cost-cutting efforts to save $100 million, following several rounds of job cuts in 2023 that eliminated 230 positions in San Diego alone.

San Diego-based DNA sequencing leader Illumina laid off 151 employees at its headquarters and a nearby site, effective August 14, 2023. This is part of a broader cost-cutting plan to reduce annual expenses by over $100 million. The layoffs, primarily affecting manufacturing, engineering, and talent acquisition roles, represent a small fraction of its global workforce of 10,200. This action occurs amidst company turmoil, including a CEO resignation, a proxy fight, and ongoing legal battles over its contested acquisition of Grail, which regulators have ordered it to divest.

Illumina on 2023-06-21.

Illumina laid off 500 employees representing approximately 5% of its workforce on 2022-11-14.